A groundbreaking study led by researchers at UCLA has unveiled persistent racial and ethnic disparities in the utilization of asthma inhalers across the United States, despite longstanding clinical guidelines that advocate for daily controller medications as the cornerstone of effective asthma management. This comprehensive analysis sheds light on the entrenched socioeconomic barriers and the critical impact of healthcare access inequities that contribute to uneven asthma treatment across diverse populations.
Asthma, a chronic respiratory condition characterized by airway inflammation and bronchial hyperresponsiveness, affects millions worldwide regardless of racial or ethnic background. Inhaled corticosteroids (ICS), long-acting beta agonists (LABA), and long-acting muscarinic antagonists (LAMA) represent the primary categories of controller inhalers prescribed to suppress inflammation and maintain airway patency over extended periods. Conversely, short-acting beta agonists (SABA) serve as rescue medications, providing rapid relief during acute exacerbations but indicating poor long-term control if over-relied upon.
Dr. Utibe Essien, assistant professor at UCLA’s David Geffen School of Medicine and the study’s senior author, emphasizes the critical need to revisit inhaler usage patterns given the evolving landscape of asthma prevalence and treatment costs over the past two decades. Previous analyses capturing inhaler access date back more than 15 years, a period preceding the widespread expansion of health insurance coverage under reforms like the Affordable Care Act. Yet, despite increased insurance enrollment and improved engagement with healthcare services, disparities in the prescription and utilization of guideline-recommended inhalers remain strikingly unchanged.
The researchers harnessed data collected from the nationally representative Medical Expenditure Panel Survey between 2014 and 2023, encompassing approximately 10,500 adults diagnosed with asthma—equating to over 1.1 million Americans. The demographic composition of this cohort was predominantly white (55%), with substantial representation from Black (20%), Hispanic (16%), and Asian (3%) populations. This rich dataset allowed for nuanced investigation of inhaler use patterns stratified by race, ethnicity, and socioeconomic factors.
Findings revealed that white adults with asthma were significantly more likely to use essential controller medications such as ICS, LABA, and LAMA inhalers when compared to their Black, Hispanic, and Asian counterparts. Specifically, 39% of white patients used ICS inhalers, contrasting with 35% of Hispanics, 34% of Blacks, and 30% of Asians. Similar trends were observed for LABA and LAMA usage, with whites consistently exhibiting higher utilization rates, underscoring systemic inequities in both medication access and asthma management quality.
Notably, the study found no statistically significant differences among ethnic groups regarding the use of SABA inhalers. While SABA medications provide necessary acute symptom relief, overreliance may indicate inadequate control of underlying inflammation and highlight potential undertreatment. The comparable rates of SABA use across groups suggest that treatment disparities are principally concentrated in controller inhaler access, rather than rescue medication use.
These disparities persisted even after adjusting for socioeconomic variables such as income, education, insurance coverage, and specialist consultation frequency. Such adjustments only partially mitigated differences in inhaler utilization, suggesting that broader systemic factors—including structural racism, healthcare policies, and provider prescribing behaviors—contribute to persistent gaps in asthma care. Dr. Essien highlights how these sociodemographic variables themselves are intricately tied to racial and ethnic disparities, complicating efforts to achieve equitable pharmacotherapy.
Another striking observation emerged regarding the short-acting inhalers, which are generally less costly and more accessible. The widest disparities appeared here too, defying expectations that lower-cost medications would exhibit more equitable distribution. This puzzling pattern signals complexities in the translation of clinical guidelines into practice, differential physician adherence to emerging recommendations, and variable patient acceptance or adherence influenced by cultural and socioeconomic contexts.
The study’s methodology, centered on robust data and statistical analysis, enables a critical reevaluation of public health strategies aimed at bridging treatment divides. It calls for in-depth exploration into healthcare provider prescribing patterns, patient education, and systemic factors that govern access to specialty care—elements crucial for tailoring interventions that promote pharmacologic equity and improved asthma outcomes.
Dr. Jing Ren, health sciences clinical instructor at UCLA and lead author of the study, alongside co-authors from UCLA and USC, underscores the transformative potential of policy reforms and targeted healthcare delivery modifications to mitigate disparities. However, the persistence of these gaps even in an era of expanded insurance access suggests that affordability is only one facet of a multifactorial problem demanding coordinated efforts at multiple levels.
This research, funded in part by the National Heart, Lung, and Blood Institute, highlights an urgent public health imperative: to understand and dismantle the barriers preventing equitable use of asthma controller inhalers among marginalized populations. Achieving this goal is not only vital for reducing asthma-related morbidity and mortality but also for fostering health justice in respiratory medicine.
As the medical community digests these findings, future research avenues are ripe for investigation. These include scrutinizing clinician adherence to guideline-based prescribing, patient trust in healthcare systems, cultural competency training, and the efficacy of community-based interventions in promoting optimal asthma care across diverse populations.
In conclusion, while advances in asthma therapeutics and healthcare coverage have proliferated over the past decades, this landmark study elucidates that significant racial and ethnic disparities in controller inhaler usage remain entrenched. Addressing these inequities calls for a concerted, multidisciplinary approach encompassing policy change, provider education, and patient empowerment to ultimately ensure that effective asthma management is equitable and accessible for all.
Subject of Research: People
Article Title: Disparities in Inhaler Utilization Among US Adults With Asthma
News Publication Date: 18-May-2026
Web References: http://dx.doi.org/10.1001/jama.2026.7613
References: Published in JAMA, 2026
Keywords: Asthma, Health Disparity, Ethnicity, Socioeconomics
